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Creation of an Influenza B Epigraph Vaccine
Leigh Jahnke, Kristine Hoagstrom, Eric Weaver
Abstract

Introduction

The CDC struggles to predict the upcoming influenza
viruses resulting in an ineffective influenza vaccine. The
2019 – 2020 influenza vaccine provides an example of
vaccine mismatch where the vaccine poorly matches the
circulating influenza strains. We have created Influenza B
Epigraph hemagglutinin (HA) immunogens that are
computationally designed to select the greatest coverage
of B and T cell epitopes in the natural population. Our
preliminary data shows Epigraph immunogens induce
superior cross-reactive antibody responses, overall T cell
immunity, breadth of T cell epitopes, and protection
against influenza virus. The primary goal of this study is
to clone the influenza B Epigraph HA immunogens into
DNA and Adenoviral mammalian expression systems.
We will characterize these novel HA immunogens for the
prevention of influenza B virus infections. Ultimately, we
seek to develop novel universal influenza vaccines that
provide a foundation of immunity which protects against
all past, present, and future influenza viruses.

• There are two strains of the Influenza B virus
o B/Yamagata/16/88
o B/Victoria/2/87
• The 2019-2020 flu season had a significantly higher
incidence of influenza B compared to past flu seasons

Methods
• Three B/Victoria/2/87 and three B/Yamagata/16/88
epigraph genes were created
• The 6 different epigraph genes were originally
received in a pMA-T backbone
•

Each gene was then amplified, confirmed, and
ligated into the plasmid pshuttle-CMV

•

This plasmid was then amplified, confirmed, and
linearized with pMeI in order to co-transform each
pshuttle-CMV epigraph gene and an Adenovirus
plasmid (pAd-Easy-1) into E.coli cells (BJ5183s)

Figure 2. Positive Influenza virus cases during the 2019-2020 flu
season where the Influenza B (green) was heavily prevalent.

Future Steps
After the cloning of pAd-Easy-Vic1, pAd-Easy-Vic2, pAdEasy-Vic3, pAd-Easy-YAM1, pAd-Easy-YAM2, pAdEasy-YAM3 is complete, each of the six genes will be
rescued in cell culture, thus creating a mammalian
expression vector. Each gene will be transfected into 293T
cells, which are derived from a human embryonic kidney.
This cell line will be used because of its high
transfectability and its high titer production when producing
retroviruses. In order to amplify the virus, consecutive
infections into greater quantity of cells will be conducted.
Once the virus is amplified to an adequate concentration, it
will be moved to the next stage involving infection into
Mus musculus. After that is successful, we will confirm
protein expression by Western blot. Western blotting
involves transferring proteins that are separated by gel
electrophoresis to a membrane where the proteins are
analyzed. This research project will take a considerable
amount of time which is why it was not fully completed
during this past academic semester.

Acknowledgements
Thank you to Dr. Eric Weaver, Brigette Corder, Bria
Bullard, and the University of Nebraska - Lincoln for
supporting this research and providing us with the
opportunity to further develop our research skills.
Figure 3. Positive Influenza virus cases during the 2018-2019 flu
season where the Influenza B (green) was not significantly prevalent.
Figure 1. Model of Influenza Virus

Figure 4. Cloning strategy for inserting Yamagata and Victoria strains
into an Adenoviral Vector system.

